How One Drug Developer Is Addressing Health Inequities
Robert Blum, CEO of Cytokinetics, discusses hypertrophic cardiomyopathy, how the company has worked to build relationships in the black community to expand participation in clinical trials, and how it is thinking ahead to issues of access and affordability as it advances the drug towards the market.